<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="125702">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01466049</url>
  </required_header>
  <id_info>
    <org_study_id>FDI-35</org_study_id>
    <nct_id>NCT01466049</nct_id>
  </id_info>
  <brief_title>New Biomarkers Evaluating Ovarian Cancer</brief_title>
  <official_title>Evaluation of New Biomarker Assays in Ovarian Cancer Patients Presenting to a Generalist With an Adnexal Mass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujirebio Diagnostics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujirebio Diagnostics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate new biomarkers for patients presenting to a
      physician for surgery to remove a mass in their pelvis and to continue to evaluate these
      types of patients using the ROMA algorithm for post-market benefits.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate novel biomarkers for patients with an adnexal mass</measure>
    <time_frame>observational studies</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">280</enrollment>
  <condition>Adnexal Mass</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Women with an adnexal mass, presenting to a general surgeon or obstetrician/ gynecologist
        at a general or specialty center within the United States, for whom a decision to proceed
        with surgery to remove the mass has been made.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, age 18 years or older

          -  Adnexal mass present documented by imaging

          -  Scheduled to undergo surgery based on a finding of adnexal mass

          -  Able and willing to provide Informed Consent

        Exclusion Criteria:

          -  Previous history of ovarian cancer

          -  Previous history of bilateral oophorectomy

          -  Currently known to be pregnant

          -  Unable to provide informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana Dickson</last_name>
    <role>Study Director</role>
    <affiliation>Fujirebio Diagnostics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New Hanover Regional Medical Center</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <lastchanged_date>August 4, 2014</lastchanged_date>
  <firstreceived_date>November 3, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Adnexal Mass</keyword>
  <keyword>Pelvic Mass</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
